Phase I/II trial of YHI-1003 plus Capecitabine

Phase I/II trial of YHI-1003 plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221670

Enrollment

Registered

2011-12-13

Start date

2011-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Advanced Colorectal Cancer

Interventions

investigational material(s) Generic name etc : YHI-1003 INN of investigational material : Perifosine Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigationa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with recurrent or metastatic colorectal cancer (2)Patients must have failed available therapy for the treatment of advanced colorectal cancer. (3)No prior exposure to capecitabine and S-1 (4)ECOG performance status (PS) :0-1

Exclusion criteria

Exclusion criteria: (1)Patients with uncontrolled intercurrent illness (2)Female patients who are pregnant or lactating (3)Patients with known central nervous system CNS metastases

Design outcomes

Primary

Measure	Time frame
safety CTCAE v4.0	—

Secondary

Measure	Time frame
efficacy and pharmacokinetic profile RECIST ver1.1	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026